Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ALGS
#4515
Aligos Therapeutics, Inc. - Common stock
6.9
1
USD
-0.02%
Market Price
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-2.26%
Monthly Change
+67.31%
6 month change
+0.44%
Year Change
-29.42%
Previous Close
7.0
7
Open
6.9
1
Low
6.9
1
High
6.9
1
Volume
3
Markets
US Stock Market
Healthcare
Biotechnology
ALGS
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Documents
2021
Current report, Q2 FY2021
2021.04.27
Aligos Therapeutics, Inc. current report, Q2 FY2021
8-K
Current report, Q1 FY2021
2021.03.23
Aligos Therapeutics, Inc. current report, Q1 FY2021
8-K
2020
Current report, Q4 FY2020
2020.10.20
Aligos Therapeutics, Inc. current report, Q4 FY2020
8-K
1
2
3
4
5
6
7
News
Aligos Therapeutics stock maintains Buy rating at H.C. Wainwright on pevifoscorvir progress
Aligos Therapeutics stock rises on Phase 2 HBV study progress
Aligos reports progress on Phase 2 hepatitis B drug study
Aligos therapeutics appoints James Hassard as chief commercial officer
Aligos Therapeutics stock initiated with Buy rating at UBS on liver disease pipeline
Aligos reports synergistic weight loss effect with THR-β agonist
Aligos Therapeutics, Inc. (ALGS) Presents at Jefferies London Healthcare Conference 2025 Transcript
Aligos Therapeutics stock reaffirmed Buy at H.C. Wainwright
Tracking Baker Brothers Portfolio – Q2 2025 Update
Does Aligos Therapeutics (ALGS) Have the Potential to Rally 737.74% as Wall Street Analysts Expect?
Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia
RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study